Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.54 |
| ▸ | CTSL | P07711 | 9/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599903 | 0.89 | REN (0.49) | CTSSCTSLSMN1; SMN2REN | |
| SCHEMBL14987993 | 0.89 | REN (0.49) | CTSSCTSLSMN1; SMN2REN | |
| SCHEMBL14987883 | 0.84 | CTSS (0.55) | CTSSCTSLPKMSMN1; SMN2CTSB | |
| SCHEMBL3602438 | 0.84 | CTSS (0.55) | CTSSCTSLPKMSMN1; SMN2CTSB | |
| SCHEMBL12204063 | 0.81 | CTSS (0.59) | CTSSCTSLPKMSMN1; SMN2CTSB | |
| SCHEMBL6876245 | 0.80 | CTSS (0.64) | CTSSCTSLPKMSMN1; SMN2CTSB | |
| SCHEMBL15047876 | 0.77 | CTSS (0.56) | CTSSCTSLPKMSMN1; SMN2CTSB | |
| Lithium Ion SCHEMBL5523630 | 0.77 | CTSS (0.61) | CTSSCTSLPKMSMN1; SMN2CTSB | |
| SCHEMBL3608717 | 0.76 | KDM4E (0.44) | SMN1; SMN2RENALDH1A1 | |
| SCHEMBL5509776 | 0.76 | HTT (0.45) | CTSSCTSLSMN1; SMN2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CTSS 138/4885CTSL 82/4885PKM 2136/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | CTSS 138/4885CTSL 82/4885PKM 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.